# Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

> **NCT02525029** · PHASE1,PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 53 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Pregnyl®

## Key facts

- **NCT ID:** NCT02525029
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2021-05
- **Final completion:** 2022-04
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02525029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02525029, "Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02525029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*